Topics

Clinical Trials About "Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects" RSS

04:24 EST 24th February 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects" on BioPortfolio

We have published hundreds of Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects news stories on BioPortfolio along with dozens of Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects Clinical Trials and PubMed Articles about Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects Companies in our database. You can also find out about relevant Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects Drugs and Medications on this site too.

Showing "Single Multiple Dose Study ORIC Adult Healthy Subjects" Clinical Trials 1–25 of 62,000+

Extremely Relevant

Study of ORIC-101 in Healthy Adult Subjects

ORIC-GR-17001 is an open-label, single center, non-randomized, single ascending dose study in healthy male subjects and healthy female subjects of non-child bearing potential. In this study, ORIC-101 will be administered as single-ascending oral doses. The primary objective is to characterize the safety and tolerability of oral ORIC-101.


Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects

This is a single centre, open-label, non-randomised study with up to 2 parts, assessing the safety, tolerability, PK and PD of single (Part A) and multiple (Part B; optional) doses of oral GR antagonist ORIC-101.

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in healthy subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses. 4. Determine the effect of CK-3773274 on the pumping function of the heart


Study of ORIC-101 in Combination With Enzalutamide

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with enzalutamide (Xtandi®) when administered to patients with metastatic prostate cancer progressing on enzalutamide.

Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Solid Tumors

The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with other anticancer therapies when administered to patients with advanced or metastatic solid tumors.

A Multiple-Dose Study of Intravenous BNZ132‑1-40 in Healthy Adult Subjects

This study is a single-center, randomized, single‑blind, placebo (PBO)-controlled, multiple-dose study to characterize the safety, tolerability, PK, and PD of IV BNZ-1 administered to healthy adult subjects once weekly (QW) for 4 doses or once every other week (QOW) for 3 doses. Five cohorts of 6 subjects randomized 5 BNZ-1:1 PBO are planned to be enrolled in the trial. Participants will be followed for 4 weeks after the last dose for safety monitoring, and collection of PK a...

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

Study to determine the effect of multiple-dose BBT-877 on the single-dose pharmacokinetics of midazolam, the safety and tolerability of a single dose of BBT-877 administered alone and with multiple doses of itraconazole, and the effect of multiple-dose esomeprazole on the single-dose pharmacokinetics of BBT-877, in healthy adult subjects.

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Adult and Elderly Subjects

This is a combined Single and Multiple Ascending Oral Dose Study. Part 1 is a Single Ascending Dose (SAD) and Part 2 is Multiple Ascending Dose (MAD). The purpose of the study is to evaluate the safety and tolerability of single and multiple ascending oral doses of ASP7713 in healthy adult subjects. This study will also evaluate the pharmacokinetics of single and multiple ascending oral doses of ASP7713 as well as the effect of a single and multiple oral dose of ASP7713 on the...

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

The purpose of this study is to examine the safety, tolerability, and PK of various increasing single and multiple doses of VBP15 in healthy adult subjects.

A Phase 1 Double-Blind First-in-human Study of Orally Administered AL-034

This is a Phase 1 first-in-human (FIH) study evaluating single and multiple dose administration of AL-034 in healthy adult subjects. The aim is to examine the safety (including pharmacodynamic [PD] biomarker assessments), tolerability, and pharmacokinetics (PK) of increasing single ascending doses (SADs) (Part 1) and multiple ascending doses (MADs) (Part 2) of AL-034. The potential food effect will be investigated in healthy adult subjects at one or optionally 2 single dose lev...

Safety, Tolerability and Pharmacokinetics of APX001 Administered Intravenously

First In Human (FIH), randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) escalation study of approximately 80 subjects. The SAD portion of the study will enroll six cohorts of eight healthy subjects per cohort, for a total of approximately 48 healthy subjects. The MAD portion of the study will enroll four cohorts of eight healthy subjects per cohort, for a total of approximately 32 healthy subjects.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects

This is a phase 1, randomized, single-center, 3-part, FIH study to assess the safety, tolerability, pharmacokinetics (PK, or how the drug behaves in the body), and pharmacodynamics (PD, or what the drug does to the body) of single and multiple doses of CC-99677 and to characterize the effect of food on the single-dose PK of CC-99677 in healthy adult subjects.

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Subjects

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of TAK-906 in Japanese healthy male subjects.

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

The current study is designed to evaluate the safety, tolerability and pharmacokinetics of PF-05221304 in healthy Japanese adult subjects following single and multiple dose administration.

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

This is a phase 1, randomized, single-center, 3-part, study to assess the safety, tolerability, PK, and PD, of single and multiple doses of CC-92252 in healthy adult subjects and multiple doses of CC-92252 in adult subjects with psoriasis.

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

This clinical trial is the first-in-human study of BBT-401-1S. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.

Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses

A double-blind, placebo-controlled, single ascending dose (SAD) study is planned to assess safety, pharmacokinetics (PK), and pharmacodynamics of LBS-008 in healthy adult volunteers. Healthy male or female adults with no significant ocular abnormalities will be enrolled. The plan is to enroll 48 subjects, in six cohorts of eight subjects each; additional cohorts (eight subjects per cohort) may be enrolled if it is deemed appropriate by the sponsor to repeat a dose level or to s...

A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers

This is a Phase 1, double-blind, randomized, placebo-controlled, single-dose and multiple-dose study of CRN01941 in up to 119 healthy male and female subjects. This single-center study will be conducted in 3 parts: a single-ascending dose phase (up to 8 cohorts, 8 subjects/cohort), a multiple-ascending dose phase (up to 5 cohorts, 9 subjects/cohort), and single dose phase in elderly subjects (1 cohort, 10 subjects).

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-072 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of ketoconazole on steady state ABT-072 pharmacokinetics.

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects

Multiple Dose Study Of PF-05251749 In Healthy Volunteers

This is the first clinical trial to evaluate ascending multiple oral doses in healthy adult and healthy elderly subjects to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-05251749.

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

Study design: - Phase I, first-in-human, randomized, double-blind, placebo-controlled, sequential dose escalation study of intravenously administered HM10760A in healthy adult Caucasian and Japanese subjects. Up to 5 dose level cohorts are planned. In each dose level cohort, subjects will be randomized to receive a single dose of HM10760A or placebo. Primary Objective: - To evaluate safety profile of single intravenous (IV) dose levels of HM10760...

Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese Population

This is a single-dose and multiple-dose, open-label, single-centre pharmacokinetic (PK) study which will be conducted in Phase I Clinical Trial Centre, Chinese University of Hong Kong, to evaluate pharmacokinetics (PK) of different levels of single-dose and multiple-dose of bilastine in healthy Chinese subjects.

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

This first-in-human study, designed to assess the safety, tolerability, and pharmacokinetics (PK) of single oral ascending doses of E2027, will be administered to healthy adult subjects to determine the maximum tolerated dose (MTD). Thereafter, the pharmacodynamic (PD) effects of single doses of E2027 on elevation of cerebrospinal fluid (CSF) cyclic guanidine monophosphate (cGMP) in healthy adult subjects will be evaluated across a broad dose range, to establish the PK/PD relat...


More From BioPortfolio on "Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects"

Quick Search